Plain-English translation of NCT06064929 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested , a new medication given by IV infusion, to see if it could safely treat lupus nephritis—a serious condition where the immune system damages the kidneys in people with lupus. The study examined whether this medication could reduce kidney inflammation and slow kidney damage in people whose kidneys had not improved with standard treatments.
Lupus nephritis is hard to treat, and many patients do not respond well enough to current standard medications, leaving them at risk of kidney failure. This trial was designed to learn whether this medication could offer a new treatment option for people who need better ways to protect their kidney function.
Participants received IV infusions of the medication in two separate treatment courses, with a 28-week break between them. The trial was split into two parts: participants had to complete Part 1 before moving into Part 2. Throughout the study, participants attended clinic visits for blood tests, urine tests, and checkups to monitor how their kidneys responded to the medication and to watch for any side effects.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States